Objectives: Recent studies have raised concerns regarding usage of opioids, a class of drugs widely used for managing chronic pain in musculoskeletal disorders; however, its potential risks remain incompletely understood. This study aimed to evaluate the association between oral opioid use and mortality in a nationwide inflammatory arthritides (IA) cohort.
Methods: Data were obtained from the National Health Insurance Sharing Service database in South Korea, including 161 907 patients with seropositive rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis between 2010 and 2022. Patient demographics, laboratory variables, and medication use were recorded. Mortality risk associated with oral opioid use was evaluated using time-dependent Cox proportional hazards models, and a 6-month lagged analysis was conducted to consider the delayed effects of oral opioid exposure on mortality.
Results: Oral opioid use was associated with increased patient mortality (hazard ratio [HR] 1.60, 95% confidence interval [CI] 1.11-2.32, p= 0.012), with this association remaining significant even in the 6-month lag-adjusted model (HR 1.71, 95% CI 1.15-2.54, p= 0.008). The annual prescription rate of oral opioids increased steadily during the study period, reaching 47.5% by 2022. In subgroup analyses, male patients had significantly higher mortality risk associated with oral opioid use, whereas this risk was not evident among female patients.
Conclusion: Oral opioids, prescribed to a substantial proportion of patients with IA, were associated with higher mortality, particularly among male patients. These findings emphasise that cautious opioid prescription is required in this population, and seeking alternative pain management approaches may be warranted to improve patient outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/rheumatology/keaf135 | DOI Listing |
Rheumatology (Oxford)
March 2025
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Objectives: Recent studies have raised concerns regarding usage of opioids, a class of drugs widely used for managing chronic pain in musculoskeletal disorders; however, its potential risks remain incompletely understood. This study aimed to evaluate the association between oral opioid use and mortality in a nationwide inflammatory arthritides (IA) cohort.
Methods: Data were obtained from the National Health Insurance Sharing Service database in South Korea, including 161 907 patients with seropositive rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis between 2010 and 2022.
PLoS One
March 2025
Department of Pharmacology, Addiction Science and Toxicology, University of Tennessee Health Science Center, Memphis, Tennessee, United States.
Oxycodone abuse frequently begins with prescription oral oxycodone, yet vulnerability factors (e.g. sex, genetics) determining abuse are largely undefined.
View Article and Find Full Text PDFJ Addict Med
March 2025
From the Departments of Family and Community Medicine and Public Health Science, College of Medicine, Pennsylvania State University, Hershey, PA (W-JT); Department of Family and Community Medicine, College of Medicine, Pennsylvania State University, Hershey, PA (KTC, JS); College of Medicine, Pennsylvania State University, Hershey, PA (EJ); and Departments of Family and Community Medicine, Anesthesiology and Perioperative Medicine, and Public Health Science, Pennsylvania State University, Hershey, PA (AEZ).
Objectives: In early 2022, based on limited case-report evidence, the US Food and Drug Administration warned about possible oral health problems associated with transmucosal (sublingual, buccal) buprenorphine formulations commonly used to treat opioid use disorder (OUD). The purpose of this study was to assess the risk of adverse oral health outcomes among adults prescribed transmucosal buprenorphine for OUD.
Methods: This retrospective cohort study utilizing TriNetX claims data consisted of adults diagnosed with OUD in 2002-2019, and who either filled ≥3 transmucosal buprenorphine prescriptions within any 6-month period (buprenorphine cohort) or did not fill any buprenorphine prescriptions (control cohort).
Front Oral Health
February 2025
Department of Conservative Dentistry and Periodontology, University Hospital Regensburg, Regensburg, Germany.
Objectives: Opioid use has significantly increased in Germany in recent years. This study aimed to evaluate and compare the oral health, dental hygiene, self-perceived pain, and functional limitations of opioid-addicted patients with a healthy control group.
Materials And Methods: 50 opioid-addicted patients (OAP) attending substitution treatment at the Centre for Addiction Medicine of the Department of Psychiatry and Psychotherapy at the University of Regensburg were enrolled and interviewed about their drug use history.
J Subst Use Addict Treat
March 2025
University of North Carolina at Chapel Hill, Department of Health Behavior, 135 Dauer Dr., Chapel Hill, NC 27599, USA.
Background: Stigma in people who use drugs predicts treatment engagement, psychosocial health, and overdose, yet there are few evidence-based interventions to support people who use drugs in managing and coping with substance-related stigma and even fewer for people in active use. mHealth is one option to engage this hard-to-reach population.
Methods: Premised on the theory of stigma resistance, this mixed-methods study explored the feasibility, acceptability, and preliminary effectiveness of Project RESTART, a four-week, automated text message intervention for rural-dwelling people who use drugs (n = 30) using a one-group pre-post design.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!